TAMPA, Fla.–(BUSINESS WIRE)–Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI) today announced that the Company and leading physicians from Johns Hopkins University co-hosted a meeting with prospective clinical trial investigators at the recent American Academy of Neurology (AAN) Annual Meeting in New Orleans. The Company and investigators from Johns Hopkins University presented plans for a randomized clinical trial to study Cyrevia™ (formerly Revimmune™) in multiple sclerosis (MS) to a number of key opinion leaders in the field and potential site investigators. Johns Hopkins University will serve as the lead trial site for the study.
so that you can be kept up to date with MS News and Information
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
LIKE this BLOG? – Please click the LIKE button top left